Darolutamide in the Treatment of Non-Metastatic Castration Resistant Prostate Cancer & Darolutamide in Combination with Docetaxel for Metastatic Hormone Sensitive Prostate Cancer

In an effort to promote higher quality patient care, NCODA created the NCODA Positive Quality Intervention (PQI) as a precise and concise peer-reviewed clinical guidance resource for healthcare professionals. By providing Quality Standards and effective practices around specific aspects of cancer care, PQIs equip the entire multidisciplinary care team with a sophisticated yet simple resource for managing patients receiving oral or intravenous anti-cancer agents. This PQI in Action is a follow up to the NUBEQA® (darolutamide) PQIs. It explores how the medically integrated teams at Stockton Hematology Oncology Medical Group and The American Oncology Network (AON) incorporate PQIs as part of their daily workflow. It will discuss how utilizing the Darolutamide In the Treatment of Non-Metastatic Castration Resistant Prostate Cancer and the Darolutamide in combination with Docetaxel for Metastatic Hormone Sensitive Prostate Cancer PQIs elevates patient care and experience.